Using mice to treat (wo)men: mining genetic changes in patient xenografts to attack breast cancer

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Endocrine therapy is a cornerstone treatment for estrogen receptor-positive breast cancer.
• Tumor resistance to endocrine therapy remains a significant clinical challenge.
• Understanding the genetic underpinnings of resistance is crucial for developing effective therapeutic strategies.

Purpose of the Study:

• To investigate the evolutionary genetic landscape of endocrine-resistant breast cancer.
• To identify specific genetic alterations driving resistance to endocrine therapy.
• To leverage patient-derived xenografts (PDXs) as a model for studying tumor evolution.

Main Methods:

• Analysis of genetic alterations in patient-derived xenografts (PDXs) across different stages of endocrine therapy response.
• Whole-exome sequencing and targeted gene sequencing to identify mutations.
• Functional assays to assess the impact of identified mutations on estrogen receptor activity.

Main Results:

• Li et al. demonstrate that PDX models accurately recapitulate tumor evolution under endocrine pressure.
• The study identified the emergence of functional estrogen receptor (ER) mutations as a key mechanism of acquired endocrine resistance.
• These mutations confer ligand-independent ER activity, driving tumor growth despite treatment.

Conclusions:

• Genetic analysis of PDXs provides a powerful approach to dissecting tumor evolution and resistance mechanisms.
• Emergence of functional ER mutations is a critical event in the development of endocrine-resistant breast cancer.
• These findings have implications for monitoring treatment response and developing novel therapeutic interventions targeting resistance pathways.